23 Feb AIVITA Biomedical
Hans Keirstead, Ph.D., CEO
AIVITA Biomedical is a personalized vaccine company designing immuno-oncology therapies that target the seed of all cancers: tumor-initiating cells. We take a unique pan-antigenic approach — targeting all neoantigens, rather than a select few — allowing our treatments to overcome cancer’s tendency to mutate over time. Our patient-specific treatments have shown tremendous promise in eradicating tumors without harmful side effects in our melanoma and glioblastoma clinical studies. We have also leveraged our approach to create a proprietary skincare line, which dedicates 100% of net proceeds towards advancing revolutionary treatments for patients with cancer, and continue to explore additional applications in human health.